EXPRESSION OF BCL-2 PROTEIN AND KI-67 NUCLEAR PROLIFERATION ANTIGEN IN BENIGN AND MALIGNANT CUTANEOUS T-CELL INFILTRATES

被引:66
作者
DUMMER, R
MICHIE, SA
KELL, D
GOULD, JW
HAEFFNER, AC
SMOLLER, BR
WARNKE, RA
WOOD, GS
机构
[1] VET AFFAIRS MED CTR,CLEVELAND,OH 44106
[2] CASE WESTERN RESERVE UNIV,DEPT DERMATOL,CLEVELAND,OH 44106
[3] CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106
[4] CASE WESTERN RESERVE UNIV,SKIN DIS RES CTR,CLEVELAND,OH 44106
[5] UNIV ZURICH,SCH MED,DEPT DERMATOL,ZURICH,SWITZERLAND
[6] VET AFFAIRS MED CTR,CTR MOLEC BIOL MED,PALO ALTO,CA 94304
[7] STANFORD UNIV,MED CTR,STANFORD,CA 94305
关键词
D O I
10.1111/j.1600-0560.1995.tb00733.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The bcl-2 protein prolongs cell life by inhibiting apoptosis. Its expression has been studied in a variety of normal tissues and lymphomas but there is minimal information available concerning bcl-2 expression by benign and malignant cutaneous T-dells. Therefore, we investigated bcl-2 expression in a wide variety of cutaneous T-cell infiltrates using one- and two-color immunohistologic techniques. bcl-2 was expressed by the majority of lesional CD3(+) T-cells in most cases. This included 22/26 cases of mycosis fungoides (MF), 3/3 cases of non-MF cutaneous T-cell lymphoma, 5/5 cases of lymphomatoid papulosis, 4/4 cases of T-cell rich cutaneous lymphoid hyperplasia, 2/3 cases of bullous pemphigoid, 2/2 cases of discoid lupus erythematosus and 1/1 case of lichen planus. Titration experiments and comparative studies of tonsil section positive controls revealed that, relative to mantle zone B-cells, there was over- expression of bcl-2 by a variable subset of T-cells in most cases. Assessment of multiple biopsies in a subset of MF cases showed stable expression of bcl-2 over intervals of up to two years. In contrast to the widespread expression of bcl-2 in both early and advanced MF skin lesions, abundant expression of the nuclear proliferation antigen, Ki-67, was skewed toward advanced MF skin lesions. Ten percent or more Ki-67(+) cells were present in 5% of patients with patches/thin plaques, 38% with moderate plaques, 64% with thick plaques and 100% with tumor nodules. Two-color immunohistologic analysis combined with molecular biologic analysis of clonality in the cases of T-cell rich cutaneous lymphoid hyperplasia indicated that bcl-2 expression was both a polyclonal and multilineage phenomenon, suggesting that it occurred by a physiologic rather than mutational mechanism. We conclude that bcl-2 expression is a common feature of cutaneous T-cell infiltrates that has minimal differential diagnostic value for distinguishing lymphomas from reactive T-cell infiltrates. In early MF lesions, abundant expression of bcl-2 and sparse expression of Ki-67 suggested that the accumulation of tumor cells during the initial progression of MF may be facilitated by prolonged clonal survival in conjunction with low-grade clonal proliferation.
引用
收藏
页码:11 / 17
页数:7
相关论文
共 38 条
[1]   MYCOSIS-FUNGOIDES - CLINICAL AND HISTOLOGIC FEATURES, STAGING, EVALUATION, AND APPROACH TO TREATMENT [J].
ABEL, EA ;
WOOD, GS ;
HOPPE, RT .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (02) :93-115
[2]   VARIANT TRANSLOCATION OF THE BCL-2 GENE TO IMMUNOGLOBULIN-LAMBDA LIGHT CHAIN GENE IN CHRONIC LYMPHOCYTIC-LEUKEMIA [J].
ADACHI, M ;
COSSMAN, J ;
LONGO, D ;
CROCE, CM ;
TSUJIMOTO, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) :2771-2774
[3]   ADVANTAGES OF DETECTING MONOCLONAL-ANTIBODY BINDING TO TISSUE-SECTIONS WITH BIOTIN AND AVIDIN REAGENTS IN COPLIN JARS [J].
BINDL, JM ;
WARNKE, RA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1986, 85 (04) :490-493
[4]  
BORZILLO GV, 1992, ONCOGENE, V7, P869
[5]   BCL-2 PROTEIN EXPRESSION AND CORRELATION WITH THE INTERCHROMOSOMAL-1418 TRANSLOCATION IN CUTANEOUS LYMPHOMAS AND PSEUDOLYMPHOMAS [J].
CERRONI, L ;
VOLKENANDT, M ;
RIEGER, E ;
SOYER, HP ;
KERL, H .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (02) :231-235
[6]  
CHILDRESS L, IN PRESS LAB INVEST
[7]   CYTOGENETIC AND MOLECULAR STUDIES OF T(14-18) AND T(14-19) IN NODAL AND EXTRANODAL B-CELL LYMPHOMA [J].
CLARK, HM ;
JONES, DB ;
WRIGHT, DH .
JOURNAL OF PATHOLOGY, 1992, 166 (02) :129-137
[8]   INTERLEUKIN-7 IS A GROWTH-FACTOR FOR SEZARY LYMPHOMA-CELLS [J].
DALLOUL, A ;
LAROCHE, L ;
BAGOT, M ;
MOSSALAYI, MD ;
FOURCADE, C ;
THACKER, DJ ;
HOGGE, DE ;
MERLEBERAL, H ;
DEBRE, P ;
SCHMITT, C .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) :1054-1060
[9]   INTERLEUKIN-4 PROTECTS CHRONIC LYMPHOCYTIC LEUKEMIC B-CELLS FROM DEATH BY APOPTOSIS AND UP-REGULATES BCL-2 EXPRESSION [J].
DANCESCU, M ;
RUBIOTRUJILLO, M ;
BIRON, G ;
BRON, D ;
DELESPESSE, G ;
SARFATI, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1319-1326
[10]   SUPPRESSION OF APOPTOSIS IN A CYTOTOXIC T-CELL LINE BY INTERLEUKIN 2-MEDIATED GENE-TRANSCRIPTION AND DEREGULATED EXPRESSION OF THE PROTOONCOGENE BCL-2 [J].
DENG, G ;
PODACK, ER .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (06) :2189-2193